About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2025№7
Statement of the meeting of...

Statement of the meeting of the Council of Experts of the Russian Association for Human Reproduction (RAHR) on the topic: «Features of the use of estrogens and progestogens in programs of assisted reproductive technologies»

DOI
https://dx.doi.org/10.18565/aig.2025.186

For citation: Statement of the meeting of the Council of Experts of the Russian Association for Human Reproduction (RAHR) 
on the topic: «Features of the use of estrogens and progestogens in programs of assisted reproductive technologies».
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (7): 193-198 (in Russian)
https://dx.doi.org/10.18565/aig.2025.186

Full text (in Russian)

References

  1. Barker D., Barker M., Fleming T., Lampl M. Developmental biology: Support mothers to secure future public health. Nature. 2013; 504(7479): 209-11. https://dx.doi.org/10.1038/504209a
  2. Barker D.J., Thornburg K.L. The obstetric origins of health for a lifetime. Clin. Obstet. Gynecol. 2013; 56(3): 511-9. https://dx.doi.org/10.1097/GRF.0b013e31829cb9ca
  3. Guan S., Feng Y., Huang Y., Huang J. Progestin-primed ovarian stimulation protocol for patients in assisted reproductive technology: a meta-analysis of randomized controlled trials. Front. Endocrinol (Lausanne). 2021; 12: 702558. https://dx.doi.org/10.3389/fendo.2021.702558
  4. Bodepudi R., Spence M., Repaka A., Harirah H.M., Puder K.S., Sagrillo-Fagundes L. et al. Myoinositol Versus metformin in the treatment of polycystic ovarian syndrome: a systematic review. Cureus. 2023; 15(7): e41748. https://dx.doi.org/10.7759/cureus.41748.
  5. Palacios C., Kostiuk L.K., Peña-Rosas J.P. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst. Rev. 2019; (7): CD008873. https://dx.doi.org/10.1002/14651858.CD008873.pub4
  6. Mathyk B., Schwartz A., DeCherney A., Ata B. A critical appraisal of studies on endometrial thickness and embryo transfer outcome. Reprod. Biomed. Online. 2023; 47(4): 103259. https://dx.doi.org/10.1016/j.rbmo.2023.103259
  7. Fedele L., Bianchi S., Frontino G. Aromatase inhibitors for ovulation induction in women with polycystic ovary syndrome. Fertil. Steril. 2006; 85(3): 535-7.
  8. Междисциплинарная ассоциация специалистов репродуктивной медицины (МАРС). Прегравидарная подготовка. Клинический протокол. М.: StatusPraesens; 2024. [Interdisciplinary Association of Reproductive Medicine Specialists. Pregravid preparation. Clinical protocol. Мoscow: StatusPraesens; 2024. (in Russian)].
  9. Министерство здравоохранения Российской Федерации. Женское бесплодие. Клинические рекомендации. М.; 2024. 98 с. [Ministry of Health of the Russian Federation. Female infertility. Clinical guidelines. Moscow; 2024. 98 p. (in Russian)].
  10. Wang N., Zhu Q., Li Y., Wang Q., Li D., Wang L. et al. Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin. Endocrinol. (Oxf). 2016; 84(5): 720-8. https://dx.doi.org/10.1111/cen.12997
  11. Jiang W.J., Song J.Y., Sun Z.G. Short (seven days) versus standard (fourteen days) oestrogen administration in a programmed frozen embryo transfer cycle: a retrospective cohort study. J. Ovarian Res. 2022; 15(1): 36. https://dx.doi.org/10.1186/s13048-022-00966-6
  12. Bourdon M., Santulli P., Kefelian F., Vienet-Legue L., Maignien C., Pocate-Cheriet K. et al. Prolonged estrogen (E2) treatment prior to frozen-blastocyst transfer decreases the live birth rate. Hum. Reprod. 2018; 33(5): 905-13. https://dx.doi.org/10.1093/humrep/dey031
  13. Kahraman S., Cetinkaya C.P., Cetinkaya M., Yelke H., Colakoglu Y.K., Aygun M. et al. The effect of follicle size and homogeneity of follicular development on the morphokinetics of human embryos. J. Assist. Reprod. Genet. 2017; 34(7):895-903. https://dx.doi.org/10.1007/s10815-017-0935-1
  14. Краснопольская К.В. Результаты многоцентрового проспективного сравнительного исследования применения препаратов трансдермального эстрадиола гемигидрата и перорального эстрадиола валерата у пациенток в криопротоколах программ вспомогательных репродуктивных технологий в рутинной практике. Проблемы репродукции. 2021; 27(4): 117-24. [Krasnopol’skaya K.V. The results of the multicenter prospective comparative study on the use of transdermal estradiol hemihydrate and oral estradiol valerate in cryoprotocoles of art in routine clinical practice. Russian Journal of Human Reproduction. 2021; 27(4): 117-24. (in Russian)]. https://dx.doi.org/10.17116/repro202127041117
  15. Kurtser M.A., Drapkina Yu.S., Chagovets V.V., Smolnikova V.Yu., Kalinina E.A. Priming with estradiol hemihydrate in the luteal phase prior to ovarian stimulation with GnRH antagonists: outcomes of IVF cycles in patients with previous poor response to ovarian stimulation. GREM. 2021; 2(1): 54-9.
  16. Назаренко Т.А., Корсак В.С., ред. Эстрогены в репродуктивной медицине. Рекомендации для практического применения. М.: МЕДпресс-информ; 2016. 56 c. [Nazarenko T.A., Korsak V.S., eds. Estrogens in reproductive medicine. Recommendations for practical use. Moscow: MEDpress-inform; 2016. 56 p. (in Russian)].
  17. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8. [Averkova V.G., Yureneva S.V. Quality of life in patients with premature ovarian insufficiency treated with hormone replacement therapy. Obstetrics and Gynecology. 2023; (5): 50-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.16
  18. Han Q.S., Wu Z.J., Zhou Y., Liang J.N., Jin Q.M., Song J.Y. et al. Effectiveness of oestrogen pretreatment in patients with expected poor ovarian response (POSEIDON groups 3 and 4) undergoing GnRH antagonist protocol: study protocol for a randomised controlled trial. BMJ Open. 2023; 13(8): e069840. https://dx.doi.org/10.1136/bmjopen-2022-069840
  19. Локшин В.Н., Абшекенова А.Т., Рыбина А.Н., Аскар Е., Карибаева Ш.К., Валиев Р.К. Опыт проведения программ экстракорпорального оплодотворения с донорскими ооцитами в протоколах с микронизированным прогестероном. Российский вестник акушера-гинеколога. 2023; 23(1): 70‑5. [Lokshin V.N., Abshekenova A.T., Rybina A.N., Askar E., Karibaeva Sh.K., Valiev R.K. Experience of in vitro fertilization programmes with donor oocytes in micronized progesterone protocols. Russian Bulletin of Obstetrician-Gynecologist. 2023; 23(1): 70-5. (in Russian)]. https://dx.doi.org/10.17116/rosakush20232301170
  20. Coomarasamy A., Gallos I.D., Papadopoulou A., Dhillon-Smith R.K., Al-Memar M., Brewin J. et al. Sporadic miscarriage: evidence to provide effective care. Lancet. 2021; 397(10285): 1668-74. https://dx.doi.org/10.1016/S0140-6736(21)00683-8
  21. Child T., Leonard S.A., Evans J.S., Lass A. Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles. Reprod. Biomed. Online. 2018; 36(6): 630-45. https://dx.doi.org/10.1016/j.rbmo.2018.03.005
  22. Zhao J., Hao J., Li Y. Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review. Reprod. Health. 2022; 19(1): 19. https://dx.doi.org/10.1186/s12978-022-01332-x
  23. Макарова Н.П., Краевая Е.Е., Калинин А.П. Поддержка лютеиновой фазы в программах переноса размороженных эмбрионов в полость матки у пациенток с избыточной массой тела и ожирением. Медицинский совет. 2024; (17): 52-7. [Makarova N.P., Kraevaya E.E., Kalinin A.P. Support of the luteal phase in programs for transferring thawed embryos into the uterine cavity in patients with overweight and obesity. Medical Council. 2024; (17): 52-7. (in Russian)]. https://dx.doi.org/10.21518/ms2024-442
  24. Henry A., Santulli P., Bourdon M., Maignien C., Chapron C., Treluyer J.M. et al. Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase). Hum. Reprod. Open. 2025; 2025(1): hoae072. https://dx.doi.org/10.1093/hropen/hoae072
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.